We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+22.23%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$18.5B
AUM Growth
+$2.83B
Cap. Flow
+$342M
Cap. Flow %
1.85%
Top 10 Hldgs %
16.55%
Holding
2,427
New
891
Increased
366
Reduced
546
Closed
599

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$163M
2
CCL icon
Carnival Corporation Ltd
CCL
+$137M
3
RGEN icon
Repligen
RGEN
+$104M
4
BIIB icon
Biogen
BIIB
+$104M
5
ZTS icon
Zoetis
ZTS
+$91.9M

Sector Composition

Rank Sector Weight
1 Healthcare 28.24%
2 Consumer Discretionary 12.89%
3 Financials 10.77%
4 Technology 9.62%
5 Industrials 4.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SKIN icon
526
SkinHealth Systems
SKIN
$94.9M
$5.59M 0.03%
+494,101
New +$5.32M
IIIV icon
527
i3 Verticals
IIIV
$395M
$5.57M 0.03%
167,829
+25,531
+18% +$684K
VNQ icon
528
PUT
Vanguard Real Estate ETF
VNQ
$39.9B
$5.57M 0.03%
+65,600
New +$5.44M
RNG icon
529
RingCentral
RNG
$4.05B
$5.57M 0.03%
+14,694
New +$4.57M
TXNM
530
TXNM Energy Inc
TXNM
$6.47B
$5.54M 0.03%
114,134
+108,419
+1,897% +$5.23M
HZNP
531
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.53M 0.03%
75,619
+65,684
+661% +$4.88M
TNC icon
532
Tennant Co
TNC
$1.5B
$5.5M 0.03%
78,387
+11,078
+16% +$727K
FTOCW
533
CALL
DELISTED
FTAC Olympus Acquisition Corp. Warrant
FTOCW
$5.49M 0.03%
+533,331
New +$643K
CHNG
534
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$5.49M 0.03%
294,467
-224,434
-43% -$3.69M
G icon
535
Genpact
G
$5.3B
$5.47M 0.03%
+132,355
New +$5.23M
FDS icon
536
Factset
FDS
$9.05B
$5.47M 0.03%
16,456
-5,439
-25% -$1.8M
RRX icon
537
Regal Rexnord
RRX
$14.2B
$5.46M 0.03%
44,424
-15,269
-26% -$1.69M
VRTU
538
DELISTED
Virtusa Corporation
VRTU
$5.45M 0.03%
106,625
-4,942
-4% -$248K
MCHP icon
539
Microchip Technology
MCHP
$42.8B
$5.45M 0.03%
+78,876
New +$4.91M
CX icon
540
Cemex
CX
$17.4B
$5.44M 0.03%
+1,051,584
New +$4.82M
SIX
541
DELISTED
Six Flags Entertainment Corp.
SIX
$5.43M 0.03%
159,324
+109,307
+219% +$3M
INTC icon
542
Intel
INTC
$466B
$5.4M 0.03%
+108,454
New +$5.3M
SBS icon
543
Sabesp
SBS
$19.7B
$5.39M 0.03%
+3,233,666
New +$5.24M
KMX icon
544
CarMax
KMX
$8.27B
$5.38M 0.03%
56,996
-30,038
-35% -$2.82M
RIO icon
545
Rio Tinto
RIO
$148B
$5.38M 0.03%
71,517
+66,944
+1,464% +$4.4M
MTN icon
546
Vail Resorts
MTN
$5.19B
$5.37M 0.03%
+19,248
New +$4.97M
NEE icon
547
NextEra Energy
NEE
$187B
$5.34M 0.03%
69,244
+63,552
+1,117% +$4.75M
HIMX
548
Himax Technologies
HIMX
$2.2B
$5.34M 0.03%
+722,177
New +$3.69M
RPLA
549
DELISTED
Replay Acquisition Corp. Ordinary Shares
RPLA
$5.32M 0.03%
511,377
+11,377
+2% +$116K
ORGN
550
DELISTED
Origin Materials
ORGN
$5.32M 0.03%
+16,667
New +$4.98M

Similar funds

Marshall Wace's Q4 2020 Portfolio in Review

As of Q4 2020, Marshall Wace held 2,427 positions worth $18.5B, up 18% from $15.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Marshall Wace's Q4 2020 filing shows 891 new, 366 increased, 546 reduced and 599 closed positions. Its largest new stake was Natera: 911,254 shares worth $90.7M. The largest sale was Alphabet (Google) Class A, an estimated $173M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Marshall Wace's largest Q4 2020 buy was Natera: 911,254 shares worth $90.7M.
  • Marshall Wace added most to Thermo Fisher Scientific in Q4 2020, an estimated $163M increase.
  • Marshall Wace's biggest Q4 2020 reduction was Alphabet (Google) Class A, cutting an estimated $173M.
  • Marshall Wace fully exited FedEx in Q4 2020, selling an estimated $69.6M.
  • Marshall Wace's ten largest holdings make up 17% of its $18.5B portfolio in Q4 2020.
  • Marshall Wace opened 891 new positions and closed 599 in Q4 2020.
  • Marshall Wace's portfolio value rose 18% quarter-over-quarter to $18.5B.

Based on Marshall Wace's 13F filing for Q4 2020, filed 16 Feb 2021.